Patient-derived tumor xenografts: transforming clinical samples into mouse models.

Tumor graft models (also known as patient-derived xenografts or PDX) are based on the transfer of primary tumors directly from the patient into an immunodeficient mouse. Because PDX mice are derived from human tumors, they offer a tool for developing anticancer therapies and personalized medicine for patients with cancer. In addition, these models can be used to study metastasis and tumor genetic evolution. This review examines the development, challenges, and broad use of these attractive preclinical models.

[1]  Daniel J. Freeman,et al.  Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models. , 2013, Neoplasia.

[2]  Jinghui Zhang,et al.  Analysis of MDM2 and MDM4 Single Nucleotide Polymorphisms, mRNA Splicing and Protein Expression in Retinoblastoma , 2012, PloS one.

[3]  Philippe Dessen,et al.  Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer , 2012, Clinical Cancer Research.

[4]  Robert M Hoffman,et al.  Multi‐color palette of fluorescent proteins for imaging the tumor microenvironment of orthotopic tumorgraft mouse models of clinical pancreatic cancer specimens , 2012, Journal of cellular biochemistry.

[5]  Horatiu Voicu,et al.  Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. , 2012, Neuro-oncology.

[6]  M. Hidalgo,et al.  Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Kun Yang,et al.  Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients , 2011, Cell Research.

[8]  Anne Vincent-Salomon,et al.  Molecular profiling of patient-derived breast cancer xenografts , 2012, Breast Cancer Research.

[9]  K. Debatin,et al.  Diversity of human leukemia xenograft mouse models: implications for disease biology. , 2011, Cancer research.

[10]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[11]  Pradeep S Rajendran,et al.  Single-cell dissection of transcriptional heterogeneity in human colon tumors , 2011, Nature Biotechnology.

[12]  R. Hruban,et al.  Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer , 2011, Clinical Cancer Research.

[13]  M. Hidalgo,et al.  A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.

[14]  Irene Georgakoudi,et al.  Assessment of the role of circulating breast cancer cells in tumor formation and metastatic potential using in vivo flow cytometry. , 2011, Journal of biomedical optics.

[15]  H. Iishi,et al.  Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer , 2011, Proceedings of the National Academy of Sciences.

[16]  Jennifer A. Prescher,et al.  Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models , 2010, Proceedings of the National Academy of Sciences.

[17]  B. Vonderhaar,et al.  Local regulation of human breast xenograft models , 2010, Journal of cellular physiology.

[18]  Horatiu Voicu,et al.  Abstract 4192: Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma , 2010 .

[19]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[20]  T. Sørlie,et al.  Molecular profiling and characterization of luminal‐like and basal‐like in vivo breast cancer xenograft models , 2009, Molecular oncology.

[21]  S. Patnaik,et al.  Lung cancer xenografting alters microRNA profile but not immunophenotype. , 2009, Biochemical and biophysical research communications.

[22]  M. Robinson,et al.  Human-in-Mouse breast cancer model , 2009, Cell cycle.

[23]  S. Richon,et al.  Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness , 2009, British Journal of Cancer.

[24]  I. Fichtner,et al.  Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers , 2009, Journal of Oncology.

[25]  Giovanni Parmigiani,et al.  A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.

[26]  M. Hidalgo,et al.  Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients , 2009, Clinical pharmacology and therapeutics.

[27]  Douglas B. Evans,et al.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice , 2009, Nature Protocols.

[28]  Michael Becker,et al.  Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers , 2008, Clinical Cancer Research.

[29]  J. Khan,et al.  Molecular Characterization of the Pediatric Preclinical Testing Panel , 2008, Clinical Cancer Research.

[30]  Joseph Zeidner,et al.  The pediatric preclinical testing program: Description of models and early testing results , 2007, Pediatric blood & cancer.

[31]  A. Vincent-Salomon,et al.  A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.

[32]  T. Metz,et al.  Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. , 2007, Cancer genomics & proteomics.

[33]  I. Fidler,et al.  Murine models to evaluate novel and conventional therapeutic strategies for cancer. , 2007, The American journal of pathology.

[34]  Peter J Houghton,et al.  Establishment of human tumor xenografts in immunodeficient mice , 2007, Nature Protocols.

[35]  B. Dutrillaux,et al.  Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. , 2007, Cancer research.

[36]  Peter Houghton,et al.  Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. , 2007, Cancer research.

[37]  R. Hruban,et al.  An In vivo Platform for Translational Drug Development in Pancreatic Cancer , 2006, Clinical Cancer Research.

[38]  E. Sausville,et al.  Contributions of human tumor xenografts to anticancer drug development. , 2006, Cancer research.

[39]  S. Hirohashi,et al.  Orthotopic Transplantation Models of Pancreatic Adenocarcinoma Derived From Cell Lines and Primary Tumors and Displaying Varying Metastatic Activity , 2004, Pancreas.

[40]  A. Maier,et al.  Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. , 2004, European journal of cancer.

[41]  I. Fichtner,et al.  Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. , 2004, European journal of cancer.